Pathological Complete Response to Neoadjuvant Alectinib in Unresectable Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer: A Case Report

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2023 Aug 25

PMID 37621597

Authors

Lu-Ming Wang

Peng Zhao

Xu-Qi Sun

Feng Yan

Qian Guo

Affiliations

Soon will be listed here.

Abstract

Background: The development of anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) has remarkably improved the prognosis of patients with ALK-positive advanced non-small cell lung cancer (NSCLC). Alectinib, the second-generation ALK-TKI, has been approved as first-line treatment for advanced or metastatic NSCLC patients with ALK rearrangement. Neoadjuvant therapy can achieve tumor downstaging and eradicate occult lesions in patients with potentially resectable disease. Whether neoadjuvant alectinib can be a conversion therapy in ALK-positive advanced NSCLC patients remains unclear.

Case Summary: A 41-year-old man was pathologically diagnosed with locally advanced ALK-positive stage IIIB NSCLC. Alectinib was prescribed to induce tumor downstaging and facilitate the subsequent surgical resection. The tumor was successfully downstaged and pathological complete response was achieved. Left upper lobectomy with mediastinal lymphadenectomy was performed after tumor downstaging. The patient has continued to receive alectinib as adjuvant therapy during postoperative follow-up with a recurrence-free survival of 29 mo as of writing this report.

Conclusion: This case sheds light on the feasibility and safety of alectinib as a neoadjuvant treatment for stage IIIB NSCLC patients with ALK rearrangement. Its efficacy needs to be validated in prospective clinical trials.

Citing Articles

Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges.

Cortinovis D, Leonetti A, Morabito A, Sala L, Tiseo M Cancers (Basel). 2024; 16(14).

PMID: 39061248 PMC: 11275113. DOI: 10.3390/cancers16142610.

References

Carretero R, Sektioglu I, Garbi N, Salgado O, Beckhove P, Hammerling G . Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015; 16(6):609-17. DOI: 10.1038/ni.3159. View

Zhang C, Li S, Nie Q, Dong S, Shao Y, Yang X . Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement. J Thorac Oncol. 2018; 14(4):726-731. DOI: 10.1016/j.jtho.2018.10.161. View

Hellmann M, Chaft J, William Jr W, Rusch V, Pisters K, Kalhor N . Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014; 15(1):e42-50. PMC: 4734624. DOI: 10.1016/S1470-2045(13)70334-6. View

Zhou C, Kim S, Reungwetwattana T, Zhou J, Zhang Y, He J . Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019; 7(5):437-446. DOI: 10.1016/S2213-2600(19)30053-0. View

Leonetti A, Minari R, Boni L, Gnetti L, Verze M, Ventura L . Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial. Clin Lung Cancer. 2021; 22(5):473-477. DOI: 10.1016/j.cllc.2021.02.014. View

Yeh J, Marrone K, Forde P . Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. J Thorac Dis. 2018; 10(Suppl 3):S451-S459. PMC: 5861269. DOI: 10.21037/jtd.2018.01.109. View

Hida T, Nokihara H, Kondo M, Kim Y, Azuma K, Seto T . Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017; 390(10089):29-39. DOI: 10.1016/S0140-6736(17)30565-2. View

Shaw A, Kim D, Nakagawa K, Seto T, Crino L, Ahn M . Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25):2385-94. DOI: 10.1056/NEJMoa1214886. View

Shaw A, Yeap B, Solomon B, Riely G, Gainor J, Engelman J . Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011; 12(11):1004-12. PMC: 3328296. DOI: 10.1016/S1470-2045(11)70232-7. View

10.

Kwak E, Bang Y, Camidge D, Shaw A, Solomon B, Maki R . Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363(18):1693-703. PMC: 3014291. DOI: 10.1056/NEJMoa1006448. View

11.

Rizvi N, Rusch V, Pao W, Chaft J, Ladanyi M, Miller V . Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin Cancer Res. 2011; 17(10):3500-6. PMC: 3261615. DOI: 10.1158/1078-0432.CCR-10-2102. View

12.

Zhang C, Yan L, Jiang B, Wu Y, Zhong W . Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC. J Thorac Oncol. 2020; 15(6):e95-e99. DOI: 10.1016/j.jtho.2019.12.133. View

13.

Yue P, Zhang S, Zhou L, Xiang J, Zhao S, Chen X . Perioperative alectinib in a patient with locally advanced anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC): a case report. Transl Cancer Res. 2022; 10(8):3856-3863. PMC: 8799071. DOI: 10.21037/tcr-21-642. View

14.

Zhong W, Chen K, Chen C, Gu C, Wang J, Yang X . Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. J Clin Oncol. 2019; 37(25):2235-2245. DOI: 10.1200/JCO.19.00075. View

15.

David E, Canter R, Chen Y, Cooke D, Cress R . Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival. Ann Thorac Surg. 2016; 102(4):1101-9. PMC: 5497727. DOI: 10.1016/j.athoracsur.2016.04.058. View

16.

Cheema P, Rothenstein J, Melosky B, Brade A, Hirsh V . Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. Curr Oncol. 2019; 26(1):37-42. PMC: 6380636. DOI: 10.3747/co.25.4096. View

17.

Hu Y, Ren S, Wang R, Han W, Xiao P, Wang L . Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer. Front Pharmacol. 2022; 13:816683. PMC: 9299059. DOI: 10.3389/fphar.2022.816683. View

18.

Betticher D, Schmitz S, Totsch M, Hansen E, Joss C, von Briel C . Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006; 94(8):1099-106. PMC: 2361244. DOI: 10.1038/sj.bjc.6603075. View

19.

Wen M, Wang X, Sun Y, Xia J, Fan L, Xing H . Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer. Onco Targets Ther. 2016; 9:1989-95. PMC: 4827902. DOI: 10.2147/OTT.S100303. View